Nasus Pharma to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Nasus Pharma (NYSE: NSRX) announced management will attend two investor conferences in New York in early May 2026. Chief Financial Officer Eyal Rubin will hold 1x1 investor meetings at the Market Movers Investor Summit on May 5, 2026 and the D. Boral Capital Global Conference on May 7, 2026. Interested investors should contact sponsoring institutions to request meetings.

News Market Reaction – NSRX

+1.85%

3 alerts

+1.85% Session close to close

+2.8% Peak Tracked

$34.43M Market Cap

0.1x Rel. Volume

In the May 1 session, NSRX gained 1.85%, reflecting a mild positive market reaction. Argus tracked a peak move of +2.8% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TEL AVIV, Israel, May 01, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that Company management will participate in upcoming investor conferences. 

Market Movers Investor Summit
May 5, 2026, New York, NY
Chief Financial Officer Eyal Rubin will participate in 1x1 meetings. 

D. Boral Capital Global Conference
May 7, 2026, New York, NY
Chief Financial Officer Eyal Rubin will participate in 1x1 meetings. 

Interested investors should contact their respective representatives at the sponsoring institutions to request meetings.

About Nasus Pharma
Nasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions in the community. NS002, Nasus Pharma’s intranasal powder Epinephrine product candidate is being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers needle-free, easy-to-use alternatives. Nasus Pharma’s proprietary powder-based intranasal (“PBI”) technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity’s rich vascular network for quick absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to liquid-based nasal products. For further information about the Company, please visit www.nasuspharma.com or follow on Twitter (X) or LinkedIn.

Company Contact
Nasus Pharma Ltd.
info@nasuspharma.com

Investor Contact
Mike Moyer
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com

FAQ

When will Nasus Pharma (NSRX) management attend investor conferences in May 2026?

Nasus Pharma will attend two New York conferences on May 5 and May 7, 2026. According to the company, CFO Eyal Rubin will participate in 1x1 investor meetings at the Market Movers Investor Summit and the D. Boral Capital Global Conference.

Who from Nasus Pharma (NSRX) will participate at the May 2026 investor events?

Chief Financial Officer Eyal Rubin will represent Nasus Pharma at both events. According to the company, he will be available for one-on-one investor meetings at the Market Movers Investor Summit and the D. Boral Capital Global Conference in New York.

How can investors arrange meetings with Nasus Pharma (NSRX) at the May 2026 conferences?

Investors should contact their sponsoring institution to request meetings with Nasus Pharma management. According to the company, interested parties need to coordinate directly with the conference sponsors to schedule 1x1 meetings with CFO Eyal Rubin.

What topics will Nasus Pharma (NSRX) discuss at the May 2026 investor conferences?

The announcement lists management participation and 1x1 meetings but does not specify topics in detail. According to the company, CFO Eyal Rubin will be available for investor discussions; interested investors should request meetings through sponsoring institutions for specific agendas.

Where are the Market Movers and D. Boral Capital conferences that Nasus Pharma (NSRX) will attend?

Both events are scheduled to take place in New York, New York in early May 2026. According to the company, the Market Movers Investor Summit occurs May 5 and the D. Boral Capital Global Conference occurs May 7, 2026, with CFO meetings planned.